STAT+: Novo Nordisk lowers sales, profits forecast as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.
GLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.
Hormone Therapy Boosts Weight Loss on Tirzepatide for Postmenopausal Women
TUESDAY, Feb. 3, 2026 — Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide, according to a study published online Jan. 22 in The Lancet Obstetrics, Gynaecology…
Novo’s Next-Gen Obesity Drug Beats Wegovy On Blood Sugar Control in Phase III
While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on …
GLP-1 Pill Cut Heart Failure Events in Some Diabetes Patients
(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…
Oral Semaglutide Lowers Heart Failure Risk in People with Type 2 Diabetes
Emerging evidence suggests that oral semaglutide may reduce the risk of heart failure–related events in people with type 2 diabetes. JasonDoiy/Getty Images
Oral semaglutide may reduce heart failure events in high-risk individuals with type 2 diabetes.
The benefit appeared strongest among those with a common but hard-to-treat form of heart failure.
New CagriSema data show improvement over semaglutide
Novo Nordisk’s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes.
That was the topline result from the latest Phase 3 readout …
Wegovy pill: How does it compare to injections and what are the side effects?
Weight Loss: What I Wish I’d Known Before Taking Compounded Semaglutide
Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.